Skip to main content
OpenTrials

Clinical trial condition

Neurofibromatosis 1

Explore clinical trials studying Neurofibromatosis 1. Study availability and eligibility vary by location and protocol.

135 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

Neurofibromatosis 1 trial results

Active, not recruiting

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +14 more
Locations
  • Research Site Vienna, Austria
  • Research Site Amiens, France
  • Research Site Angers, France
  • Research Site Bordeaux, France
View all 46 locations
View Trial Details
Active, not recruiting

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

NCT05101148

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +14 more
Locations
  • Research Site Rochester, Minnesota, United States
  • Research Site Akron, Ohio, United States
  • Research Site Bydgoszcz, Poland
  • Research Site Gdansk, Poland
View Trial Details
Active, not recruiting

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +14 more
Locations
  • Research Site Akron, Ohio, United States
  • Research Site Philadelphia, Pennsylvania, United States
  • Research Site Houston, Texas, United States
  • Research Site Richmond, Virginia, United States
View all 16 locations
View Trial Details
Active, not recruiting

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT03871257

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +16 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
View all 132 locations
View Trial Details
Active, not recruiting

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915

Conditions
Bone Marrow Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +22 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
View all 57 locations
View Trial Details
Active, not recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

NCT03962543

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more
Locations
  • University of Alabama at Birmingham/Children's of Alabama Birmingham, Alabama, United States
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
View all 43 locations
View Trial Details
Active, not recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

NCT03363217

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +29 more
Locations
  • Alberta Children's Hospital Calgary, Alberta, Canada
  • Children and Women's Health Centre of British Colombia Vancouver, British Columbia, Canada
  • IWK Health Centre Halifax, Nova Scotia, Canada
  • The Hospital for Sick Children Toronto, Ontario, Canada
View Trial Details
Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +17 more
Locations
  • Research Site Gainesville, Florida, United States
  • Research Site Rockville, Maryland, United States
  • Research Site St Louis, Missouri, United States
  • Research Site Commack, New York, United States
View all 34 locations
View Trial Details

Related conditions